Krystal Biotech (KRYS) Depreciation and Depletion (2016 - 2026)

Krystal Biotech has disclosed Depreciation and Depletion across 11 years of filings, most recently posting $1.5 million for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $1.5 million, up 8.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (down 2.37% YoY), and the FY2025 annual result was $5.7 million, down 5.0% from the prior year.
• Depreciation and Depletion came in at $1.5 million for Q1 2026 at Krystal Biotech, down from $1.5 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $1.8 million in Q2 2024 to a low of $462000.0 in Q1 2022.
• The 5-year median for Depreciation and Depletion is $1.3 million (2024), against an average of $1.2 million.
• Across the five-year window, Depreciation and Depletion soared 142.91% in 2023 and decreased 27.78% in 2025, its largest moves.
• Krystal Biotech's Depreciation and Depletion stood at $1.0 million in 2022, then jumped by 43.82% to $1.5 million in 2023, then retreated by 6.67% to $1.4 million in 2024, then gained by 9.86% to $1.5 million in 2025, then fell by 1.04% to $1.5 million in 2026.
• The last three Depreciation and Depletion figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.